These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30767735)

  • 1. The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease.
    Pantelidis P; Sideris M; Viigimaa M; Avranas K; Deligkaris P; Zografou I; Lovic D
    Curr Pharm Des; 2018; 24(46):5491-5499. PubMed ID: 30767735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.
    Gravez B; Tarjus A; Jimenez-Canino R; El Moghrabi S; Messaoudi S; Alvarez de la Rosa D; Jaisser F
    PLoS One; 2013; 8(9):e73737. PubMed ID: 24040049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone receptor antagonists.
    Azizi M
    Ann Endocrinol (Paris); 2021 Jun; 82(3-4):179-181. PubMed ID: 32473789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
    Rogerson FM; Yao Y; Smith BJ; Fuller PJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
    Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
    Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
    Namsolleck P; Unger T
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
    Chrissobolis S
    Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
    Baxter JD; Funder JW; Apriletti JW; Webb P
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
    Sueta D; Yamamoto E; Tsujita K
    Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor and cardiac arrhythmia.
    Gravez B; Tarjus A; Jaisser F
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
    Lother A; Moser M; Bode C; Feldman RD; Hein L
    Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.
    Ronconi V; Turchi F; Appolloni G; di Tizio V; Boscaro M; Giacchetti G
    Curr Vasc Pharmacol; 2012 Mar; 10(2):238-46. PubMed ID: 22022770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.